Source-grounded facts extracted from Monopar Therapeutics's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Monopar Therapeutics reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $3.9 million, or $0.46 per share, EPS $0.46 per share.
“Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates”
Monopar Therapeutics reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share.
“Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share”
Monopar Therapeutics reported fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share.
“the fourth quarter and full-year 2025 financial results”
Quan Vu was appointed as Chief Financial Officer at Monopar Therapeutics.
“On February 27, 2025, the Company’s Board of Directors appointed Quan Vu, age 53, to succeed Mr. Radhakrishnan as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective March 3, 2025.”
Karthik Radhakrishnan was terminated as Chief Financial Officer at Monopar Therapeutics.
“On February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated.”
Lavina Talukdar was appointed as Director at Monopar Therapeutics.
“On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.”
Michael J. Brown resigned as Director at Monopar Therapeutics.
“Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.”
Karthik Radhakrishnan was appointed as Chief Financial Officer at Monopar Therapeutics.
“On May 23, 2024, the Company’s Board of Directors appointed, Karthik Radhakrishnan, age 53, to succeed Ms. Tsuchimoto as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective July 1, 2024.”
Kim R. Tsuchimoto departed as Chief Financial Officer at Monopar Therapeutics.
“Effective June 30, 2024, after a career spanning more than 35 years, Kim R. Tsuchimoto, the Chief Financial Officer of Monopar Therapeutics Inc. (“Monopar” or the “Company”), will be retiring.”
Monopar Therapeutics reported first quarter ended March 31, 2024 results: net income $1.6 million, EPS $0.10 per share.
“Net loss for the first quarter of 2024 was $1.6 million or $0.10 per share compared to net loss of $2.4 million or $0.19 per share for the first quarter of 2023.”
Monopar Therapeutics reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share.
“Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results”
Monopar Therapeutics received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 27, 2024, the Company received a letter from Nasdaq notifying that the Company had been granted an additional 180-day extension to August 26, 2024 (“Extended Compliance Period”) to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time during the Extended Compliance Period, the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days or up to 20 business days in certain circumstances in NASDAQ's discretion, the Staff will provide written confirmation”
Monopar Therapeutics reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share, EPS $0.14 per share.
“Monopar Therapeutics Inc. issued a press release announcing its financial results and summarized recent developments for the third quarter ended September 30, 2023.”
Monopar Therapeutics received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“August 28, 2023, Monopar Therapeutics Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Capit”
Monopar Therapeutics reported second quarter ended June 30, 2023 results: net income $2.2 million or $0.16 per share, EPS $0.16 per share.
“Net loss for the second quarter of 2023 was $2.2 million or $0.16 per share compared to net loss of $2.8 million or $0.22 per share for the second quarter of 2022.”
Monopar Therapeutics shareholders approved Ratification of selection of BPM LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-06-27 meeting.
“Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm The voting results with respect to the proposal to ratify the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2023, were as follows: For Against Abstain Broker Non- Votes 10,529,760.056 3,071.000 29,101.000 N/A Accordingly, the Company’s stockholders ratified the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2023.”
Monopar Therapeutics shareholders approved Election of six directors at the 2023-06-27 meeting.
“Proposal 1 – Election of Directors At the Annual Meeting, the voting results with respect to the proposal for the election of directors, included in the Company’s Proxy Statement on Schedule 14A for the Annual Meeting, were as follows: Director For Withheld Broker Non- Votes Christopher M. Starr, Ph.D. 8,821,107.056 89,311.000 1,651,514.000 Chandler D. Robinson, MD MBA MSc 8,824,034.056 86,384.000 1,651,514.000 Michael J. Brown, MSc 8,822,931.056 87,487.000 1,651,514.000 Raymond W. Anderson, MBA 8,822,724.056 87,694.000 1,651,514.000 Arthur J. Klausner, MBA 8,785,520.056 124,898.000 1,651,514.000 Kim R. Tsuchimoto 8,820,687.056 89,731.000 1,651,514.000 Accordingly, each of the foregoing persons was elected as a director at the Annual Meeting.”
Monopar Therapeutics reported first quarter ended March 31, 2023 results: net income $2.4 million, EPS $0.19 per share.
“Net loss for the first quarter of 2023 was $2.4 million or $0.19 per share”
Monopar Therapeutics reported financial results for fourth quarter and full year ended December 31, 2022.
“On March 23, 2023, Monopar Therapeutics Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.”
Monopar Therapeutics reported third quarter ended September 30, 2022 results: net income $2.4 million or $0.19 per share, EPS $0.19 per share.
“Monopar Therapeutics Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.”
Dr. Andrew P. Mazar departed as Chief Scientific Officer at Monopar Therapeutics.
“Dr. Andrew P. Mazar, the Company’s Co-Founder, Executive Vice President of Research and Development, Chief Scientific Officer and Board Member, will be resigning from his position with the Company and as a member of the Company’s Board of Directors effective April 8, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.